The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2026 | Dual-targeting CAR-T in R/R CLL: the potential for reducing the risk of antigen escape
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, briefly discusses the potential of dual-targeting CAR T-cell therapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). He highlights that preliminary complete remission (CR) rates in a study (NCT04186520) investigating anti-CD20/anti-CD19 CAR T-cells (LV20.19) have been promising, and suggests that this dual-targeting approach may reduce the risk of antigen escape. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, one of the abstracts that I presented at the Tandem 2026 meeting was looking at patients with CLL getting a dual-targeted CAR T-cell targeting both CD19 and CD20. What we found in that clinical trial is that dual-targeting really led to an impressive best CR rate of over 70%, which is better than we saw in the clinical trials with single-targeted CAR. In that clinical trial, only four of the 18 patients had relapsed...
So, one of the abstracts that I presented at the Tandem 2026 meeting was looking at patients with CLL getting a dual-targeted CAR T-cell targeting both CD19 and CD20. What we found in that clinical trial is that dual-targeting really led to an impressive best CR rate of over 70%, which is better than we saw in the clinical trials with single-targeted CAR. In that clinical trial, only four of the 18 patients had relapsed. And so we don’t know yet because there have not been enough relapse events to say definitively whether or not we’re going to see reduced antigen escape. But the idea of dual targeting is by hitting more than one target, you get to a deeper remission, get a prolonged progression-free survival, and reduce that risk of antigen escape.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
